Regulation of the H+-ATP synthase by IF1: a role in mitohormesis by Pau B. Esparza-Moltó et al.
Vol.:(0123456789) 
Cell. Mol. Life Sci. 
DOI 10.1007/s00018-017-2462-8
REVIEW
Regulation of the  H+-ATP synthase by IF1: a role in mitohormesis
Pau B. Esparza-Moltó1 · Cristina Nuevo-Tapioles1 · José M. Cuezva1 
Received: 24 November 2016 / Revised: 9 January 2017 / Accepted: 10 January 2017 
© The Author(s) 2017. This article is published with open access at Springerlink.com
mitohormetic response, namely ATP, ROS and target of 
rapamycin (TOR). Overall, we aim to highlight the relevant 
role of the  H+-ATP synthase and of IF1 in cellular physi-
ology and the need of additional studies to decipher their 
contributions to aging and age-related diseases.
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Introduction
Mitochondria have been traditionally regarded as the 
“power stations” of the cell since they produce most of cel-
lular energy requirements in a process known as oxidative 
phosphorylation (OXPHOS). They are also primary hubs 
of intermediary metabolism because they generate precur-
sors for the synthesis of macromolecules and synthesize 
heme and Fe-S clusters present in some proteins. However, 
this notion has been expanded in recent years after the dem-
onstration of the role played by mitochondria in the execu-
tion of cell death [1–3] and in establishing pathways to 
communicate their status to the nucleus [4, 5] and to other 
compartments [6] to adapt cellular responses to different 
programs, such as proliferation, differentiation and stress 
responses [4, 7]. Mitochondrial communication is exerted 
by signaling molecules that emanate from the organelle and 
affect by different mechanisms cell fate and behavior. Some 
of the signaling molecules include  Ca2+, reactive oxygen 
species (ROS), metabolites, such as citrate, ATP, phos-
phatidylethanolamine, and mitochondrial resident proteins 
and/or peptides encoded in mtDNA [7–15].
The dynamic fusion and fission events experienced by 
the mitochondrial reticulum are also involved in signaling 
Abstract The mitochondrial  H+-ATP synthase is a pri-
mary hub of cellular homeostasis by providing the energy 
required to sustain cellular activity and regulating the 
production of signaling molecules that reprogram nuclear 
activity needed for adaption to changing cues. Herein, we 
summarize findings regarding the regulation of the activity 
of the  H+-ATP synthase by its physiological inhibitor, the 
ATPase inhibitory factor 1 (IF1) and their functional role 
in cellular homeostasis. First, we outline the structure and 
the main molecular mechanisms that regulate the activity 
of the enzyme. Next, we describe the molecular biology of 
IF1 and summarize the regulation of IF1 expression and 
activity as an inhibitor of the  H+-ATP synthase emphasiz-
ing the role of IF1 as a main driver of energy rewiring and 
cellular signaling in cancer. Findings in transgenic mice 
in vivo indicate that the overexpression of IF1 is sufficient 
to reprogram energy metabolism to an enhanced glycoly-
sis and activate reactive oxygen species (ROS)-dependent 
signaling pathways that promote cell survival. These find-
ings are placed in the context of mitohormesis, a program 
in which a mild mitochondrial stress triggers adaptive 
cytoprotective mechanisms that improve lifespan. In this 
regard, we emphasize the role played by the  H+-ATP syn-
thase in modulating signaling pathways that activate the 
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[16–18]. The primary sensor of mitochondrial status is the 
mitochondrial membrane potential (ΔΨm) and prevent-
ing its collapse is essential for cellular viability [19]. The 
mitochondrial signalosome primarily triggers the revers-
ible and/or irreversible modification of proteins and/or 
the allosteric regulation of enzymes that result in protein 
activation/inactivation of particular genetic and/or epige-
netic programs for cellular adaptation. The list of programs 
affected by the mitochondrial signalosome is just being 
glimpse, and remarkably, some of them are responsible for 
promoting adaptive mechanisms that allow cells to with-
stand subsequent detrimental stresses, a concept coined as 
“mitohormesis” [20, 21].
A primary hub of mitochondrial energy generation 
and signaling is the OXPHOS system that integrates the 
complexes of the electron transport chain (ETC) and the 
 H+-ATP synthase in defined supercomplexes and sub-
domains of the inner mitochondrial membrane (IMM) 
[22–24]. In OXPHOS, the electrons derived from biologi-
cal oxidations are transferred to the complexes of the ETC 
to reduce molecular oxygen and to generate the proton gra-
dient used for the synthesis of ATP by the  H+-ATP syn-
thase [25, 26]. Even under conditions of efficient electron 
transfer a small percentage of the electrons funneled into 
the ETC generate superoxide radical [9], which is rapidly 
converted into the signaling molecule hydrogen peroxide. 
Its production is largely increased in pathophysiological 
situations [7, 27, 28] or could contribute to mitohormesis 
[20, 21]. This review is mainly focused on the regulation 
of the activity of the  H+-ATP synthase by its physiological 
inhibitor the ATPase inhibitory factor 1 (IF1) with empha-
sis in the different signaling pathways that contribute to 
mitohormesis as a result of its activation as inhibitor of the 
engine of OXPHOS.
The  H+-ATP synthase: a core hub 
in mitochondrial structure and function
The  H+-ATP synthase is a multisubunit complex built by 
two major functional domains: the membrane-embed-
ded  Fo-ATPase (a and 8c subunits) and the membrane-
extrinsic catalytic  F1-ATPase (3α, 3β, γ, δ and ε subu-
nits) domains [25] (Fig.  1a). Both domains are linked 
by a central stalk that contains γ, δ and ε subunits of the 
 F1-domain and a peripheral stalk that contains b, d, F6, 
and OSCP (oligomycin sensitivity-conferring protein) 
subunits [25] (Fig.  1a). Additional subunits have been 
described in the mitochondrial complex when the enzyme 
is purified in the presence of phospholipids: e, f, g, A6L, 
DAPIT (diabetes-associated protein in insulin-sensi-
tive tissues) and the 6.8-kDa proteolipid (6.8PL). Their 
role in the activity of the enzyme remains to be fully 
characterized [25, 29]. ATP synthesis by the  H+-ATP 
synthase is driven by the influx of protons into the matrix 
through the a subunit that promotes the rotation of the 
c-ring and of the attached central stalk, the later trigger-
ing the conformational changes in the  F1-ATPase that 
drives ATP synthesis from ADP and Pi [25, 30]. The 
 H+-ATP synthase is a reversible engine because ATP 
hydrolysis triggers rotation of the c-ring in the opposite 
direction generating a proton gradient across the inner 
membrane [25, 30].
The assembly of the  H+-ATP synthase in Saccharomyces 
cerevisiae comprises two separate and coordinated path-
ways that involve (1) the stepwise assembly of Atp6 (the 
homologue of a subunit) and Atp8 (the homologue of A6L 
subunit) with the peripheral stalk and (2) the assembly of 
the c-ring with the  F1-ATPase domain [31, 32]. Later steps 
in the assembly process are mediated by the INA complex, 
a matrix-exposed inner membrane protein complex that 
facilitates the assembly of the peripheral stalk [33]. The 
assembly process in humans is similar to yeast [34]. Two of 
the “supernumerary” subunits, DAPIT [35] and 6.8PL [36], 
seem to be involved in the assembly process because its 
silencing in HeLa cells causes the loss of  H+-ATP synthase 
complexes. Super-assemblies of the  H+-ATP synthase [24] 
play an important role in determining the structure of the 
mitochondrial inner membrane because they contribute to 
the generation of cristae [37]. In fact, dimeric arrays of the 
 H+-ATP synthase in the inner membrane of yeast [38] and 
mammalian mitochondria [39] generate the curvature of 
the IMM that promotes cristae formation [37, 40]. Recent 
findings suggest that while the e–g heterodimer promotes 
the local membrane curvature, the f subunit in the mono-
mers establishes the contacts in the dimer interface [41].
The ATPase inhibitory factor 1 (IF1), which is a main 
regulator of the activity of the  H+-ATP synthase (see 
below) has also been claimed to promote dimerization of 
the  H+-ATP synthase [42–47]. However, other studies do 
not support this idea [48–50] or suggest that IF1 is just a 
bridge stabilizing two  F1-ATPase domains with no crucial 
role in dimer formation [51]. Interestingly, recent find-
ings support that the mitochondrial permeability transition 
pore (PTP) [3] contains dimers of the  H+-ATP synthase 
[3, 52–54], consistent with the finding that subunit c of the 
 Fo domain is required for the activity of the PTP [55, 56]. 
Interestingly, it has been suggested that the low probabil-
ity of PTP opening at low pH might be due to the binding 
of IF1 [3] because the histidine reagent diethylpyrocarbon-
ate is able to restore the ability to induce PTP opening and 
prevents IF1 binding to the inner membrane [3]. However, 
alternative explanations for IF1-mediated protection against 
cell death have already been provided in cellular [57] and 
in  vivo mouse models [42, 58] by the mitohormetic role 
played by IF1.
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The activity of the  H+-ATP synthase is regulated by the 
cellular energy demand, the covalent modification of several 
of its subunits and by different metabolites and regulatory 
proteins that interact with the enzyme [59–62]. One of the 
key regulators of the  H+-ATP synthase activity is  Ca2+ [8]. 
Mitochondria are crucial organelles in intracellular  Ca2+ 
buffering and signaling [63, 64]. S100A1 is a  Ca2+-sensing 
protein that is expressed predominantly in cardiac mus-
cle and interacts with the  F1-ATPase in a  Ca2+-dependent 
manner, increasing its activity [65]. Consistently, S100A1 
knockout mice show reduced  H+-ATP synthase activity in 
cardiomyocytes [65]. The  Ca2+-inhibitor binding protein 
(CaBI) is another  Ca2+-sensitive protein that dissociates 
from the  H+-ATP synthase molecule in the presence of 
high intracellular  Ca2+ levels and has been suggested as a 
candidate for the regulation of the  H+-ATP synthase [61, 
66].
The major  Ca2+ store in the cell is the endoplasmic 
reticulum (ER). Contacts between mitochondria and the 
ER called mitochondria-associated membranes (MAMs), 
mediate the transfer of ions, metabolites, proteins and 
phospholipids, including  Ca2+ [6]. One important com-
plex involved in these contacts is the yeast ERMES (ER-
mitochondria encounter structure) complex [67], which is 
composed by four core proteins resident both in the ER and 
in mitochondria. These proteins are functionally connected 
to phospholipid biosynthesis and  Ca2+ signaling [67]. 
ERMES is naturally involved in establishing and maintain-
ing contact sites between the two organelles [68]. Further 
studies have revealed that ERMES is involved in mitochon-
drial dynamics, inheritance, protein import, mtDNA inher-
itance and mitophagy [69]. No orthologues of the ERMES 
complex have been found in mammals.
DAPIT, a “supernumerary” subunit of the  H+-ATP syn-
thase, may also play a role in the regulation of the  H+-ATP 
synthase since it is highly expressed in cells with high 
aerobic metabolism [70]. Knockdown of DAPIT results in 
a drastic reduction in the activity and content of  H+-ATP 
synthase complexes in human cells [35]. In contrast to 
these findings, the overexpression of DAPIT in HEK293T 
Fig. 1  Structure of the bovine  H+-ATP synthase and binding site of 
IF1. a The soluble  F1-ATPase domain is composed by the 3α3β sub-
assembly (salmon/red) and γ (dark blue), δ and ε (light blue) subu-
nits, while the membrane-embedded  Fo domain is formed by subunit 
a (red) and a ring of 8c subunits (light/dark blue). Both domains are 
linked together by a central stalk (γ, δ, ε subunits of the  F1 domain) 
and a peripheral stalk (b, d F6, A6L, OSCP subunits, in orange). The 
3D structure of the peripheral stalk is not fully resolved. Except for a 
and A6L subunits, the remainder are encoded in the nucleus. Molecu-
lar reconstruction from PDB. b Lateral and basal view of the bovine 
 F1 domain (α subunit is shown in salmon, β in red and γ in blue) 
complexed with a fragment of IF1 (green). IF1 binds to the αβ inter-
face through residues 1–37 and also contacts the γ subunit. Images 
taken from [44] (PDB: 1OHH) and created with the PyMOL Molecu-
lar Graphics System
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cells impairs mitochondrial biogenesis and promotes the 
generation of ROS, both resulting in an enhanced aerobic 
glycolysis and the activation of the Wnt/β-catenin signaling 
pathway [71].
Besides S100A1, CaBI and DAPIT, the activity of the 
 H+-ATP synthase is regulated by additional interacting pro-
teins, including the antiapoptotic protein Bcl-xL (B-cell 
lymphoma-extra-large) [72], the hypoxia-induced protein 
G0/G1 switch gene 2 (G0s2) [73] and coupling factor B 
(FB) [29]. Moreover, different covalent modifications and 
metabolites produced in mitochondria regulate the activity 
of the  H+-ATP synthase (see [62] for details).
The ATPase inhibitory factor 1 (IF1): a master 
regulator of the activity of the  H+-ATP synthase
IF1 was first described in mitochondria from bovine heart 
as a small protein that inhibits the soluble  F1 domain of the 
 H+-ATP synthase [74] (Fig.  1b) with homologs in plants, 
yeasts, animals and humans (for review see [62]). The 
mammalian proteins present a high degree of sequence 
conservation and are able to inhibit the  H+-ATP synthase 
of different species, including yeast [75]. In humans, IF1 
is encoded in the nuclear ATPIF1 gene, located in chromo-
some 1, is translated as a precursor protein that upon mito-
chondrial import experiences the removal of the N-terminal 
25-residue long pre-sequence [62]. The mature protein 
comprises a N-terminal intrinsically disordered domain 
[43] that interacts with the  H+-ATP synthase and a C-ter-
minal dimerization domain [76] (Fig.  2a). Bioinformatic 
predictions suggest that human and mouse homologues are 
also intrinsically disordered proteins (Fig. 2b). Intrinsically 
disordered proteins are important components of cellular 
signaling, since they can respond to intra- or extracellular 
cues by disorder-to-order conformational changes to exert 
a plethora of outcomes [77]. IF1 binding site is located in 
the catalytic interface between the α and β subunits of the 
 F1 domain (Fig. 1b) as inferred using a truncated form of 
bovine IF1 (I1-60His) [78]. During the binding process, 
the N-terminus of I1-60His changes to an ordered α-helical 
structure [79] and once bound, IF1 blocks the rotation of 
the complex inhibiting the hydrolysis of ATP [80] (Fig. 1b).
Recent findings point out that IF1 when bound to the 
enzyme inhibits both the ATP hydrolase and synthase 
activities [81] rather than acting solely as a unidirectional 
inhibitor of the hydrolase activity of the  H+-ATP synthase 
[25, 46]. Indeed, inhibition of the  H+-ATP synthase activity 
has been reported by the overexpression of IF1 or its con-
stitutively active mutant H49K in cells in culture [57, 82, 
83] and in neurons [58] and in hepatocytes [42] of trans-
genic mice in vivo. Consistently, it has been reported that 
IF1 inhibits the translocation of protons mediated by the 
 H+-ATP synthase when operating in synthetic and hydro-
lytic modes [84] (Fig.  3). The IF1-mediated inhibition of 
the ATP synthetic activity can also be traced by the activa-
tion of signaling pathways sensing energy deprivation and 
the subsequent activation of glycolysis [42, 57, 58, 82, 83]. 
More direct confirmation that IF1 inhibits both activities 
of the enzyme was recently provided after showing that its 
binding to the synthase and inhibitory activities depend on 
its phosphorylation status [81].
Regulation of IF1 activity and expression
The regulation of IF1 activity as an inhibitor of the hydro-
lase activity of the  H+-ATP synthase involves five histidine 
Fig. 2  IF1 is an intrinsically 
disordered protein. a Amino 
acid sequence of bovine IF1 and 
scheme of the main domains 
of the protein: the mitochon-
drial targeting sequence (MTS, 
blue), the N-terminal inhibi-
tory domain (ID, red) and the 
α-helical coiled-coil dimeriza-
tion domain (DD, yellow) are 
highlighted. b Prediction of the 
disordered regions of human 
(hIF1) and mouse IF1 (mIF1) 
using Predictor of Natural 
Disordered Regions (PONDR®) 
VLXT algorithm. The regions 
with PONDR score >0.5 are 
predicted as disordered
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residues whose ionization status play an active role in the 
structure and oligomerization of IF1 [85]. When the mito-
chondrial matrix acidifies, i.e., when mitochondria become 
de-energized, such as in hypoxia and ischemia, IF1 tends 
to form inhibitory dimers [85]. At pH higher than 6.7, IF1 
tends to form inactive tetramers by the interaction of two 
dimers through the N-terminus of the protein, hence mask-
ing the region that binds to the  H+-ATP synthase [76, 85] 
(Fig.  4). Site-directed mutagenesis of H49 into a lysine 
generates the IF1-H49K mutant, which is active as inhibi-
tor of the enzyme at pH higher than 6.7 [85] and has been 
used to effectively inhibit OXPHOS in a tissue-specific 
manner in transgenic mice [42, 58].
More recently, we have demonstrated that the inhibi-
tory activity of IF1 depends on the phosphorylation status 
of a conserved serine 39 (S39) [81]. In the dephosphoryl-
ated state, IF1 binds to the  H+-ATP synthase and inhibits 
both activities of the enzyme (Fig.  4). Phosphorylation 
Fig. 3  IF1 inhibits  H+ trans-
location through the  H+-ATP 
synthase in both synthetic and 
hydrolytic modes. a  H+ uptake 
is induced by valinomycin-
mediated  K+ release from 
 FoF1-K+ liposomes with the 
 H+-ATP synthase functioning 
in the hydrolytic mode. b  H+ 
release is induced by valino-
mycin-mediated  K+ uptake in 
 FoF1-K+ liposomes with the 
 H+-ATP synthase functioning in 
the synthetic mode. Rates of  H+ 
uptake (a) and  H+ release (b) 
are reduced when the liposomes 
are incubated with increas-
ing concentrations of isolated 
IF1. Black circle valinomycin. 
Adapted from [84]
Fig. 4  Post-translational regu-
lation of IF1 activity. IF1 can 
be inhibited by pH-dependent 
oligomerization, phosphoryla-
tion mediated by a mitochon-
drial cAMP-dependent protein 
kinase A-like activity (PKA) or 
by sequestration by a mitochon-
drial membrane protein (IF1-
BP). IF1 is also the substrate 
for acetylation, glycosylation 
and succinylation, although the 
physiological effects of these 
modifications remain to be 
fully characterized. The pool 
of active IF1 determines the 
population of inhibited  H+-ATP 
synthase complexes, which 
might trigger retrograde signal-
ing pathways
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of IF1 prevents its interaction with the  H+-ATP synthase, 
abolishing its inhibitory activity (Fig. 4). IF1 is phospho-
rylated in vivo by the activity of a mitochondrial cAMP-
dependent protein kinase [81]. Actually, PKA regulates 
diverse mitochondrial functions [62, 86], including an 
increase in the efficiency of OXPHOS [87–90].
A soluble adenylyl cyclase (sAC) has been described 
inside mitochondria [87, 91, 92], which is activated by 
 Ca2+ [89] and bicarbonate [87]. In this regard, it is inter-
esting to note that β-adrenergic stimulation of mouse 
heart in  vivo also promotes an increase in cAMP levels 
inside mitochondria, the phosphorylation of IF1 and the 
subsequent activation of the  H+-ATP synthase boosting 
ATP supply by OXPHOS [81]. We have recently sum-
marized other physiologically relevant contexts for the 
regulation of IF1 activity by phosphorylation for tuning 
substrate availability and energy demand with OXPHOS 
activity in hypoxia, cell cycle progression and cancer [62, 
81]. The mechanisms regulating the dephosphorylation 
of IF1 (if any) are unknown [62]. Nevertheless, we have 
suggested that the short half-life of the protein [83, 93] 
may rapidly reestablish the content of active dephospho-
IF1 inside the organelle.
Besides the canonical binding site on the  H+-ATP 
synthase, IF1 can also bind to OSCP [94] and to a small 
mitochondrial membrane protein that hampers its activ-
ity as an inhibitor of the  H+-ATP synthase [95] (Fig. 4). 
Hence, IF1 oligomerization, phosphorylation and bind-
ing to a putative “receptor” may regulate the pool of 
active IF1 in mitochondria, allowing OXPHOS to adapt 
to different conditions of substrate availability and 
energy demand (Fig.  4). Moreover, additional covalent 
modifications of IF1 have been reported (Fig. 4) but their 
physiological relevance remains to be investigated [62].
Table 1 summarizes and compares the expression level 
of IF1 in different human tissues. As we have observed in 
mouse heart [81], not all the IF1 present in the tissue is 
active as an inhibitor under basal physiological conditions 
[81]. In fact, and based on the findings in heart, we suggest 
that a large fraction of IF1 is maintained functionally inac-
tive (Fig.  4) in high energy-demanding tissues that show 
a high content of IF1 (brain, kidney and liver) to provide 
a reservoir of inhibitor that could prevent ATP wasting 
when OXPHOS is compromised [81]. On the other hand, 
the fraction of active IF1 inhibitor offers a pool of inactive 
 H+-ATP synthase in the tissue that upon an enhanced meta-
bolic demand could respond increasing the supply of ATP 
after the inactivation of IF1 (Fig. 4) [81]. We suggest that 
this pool of inactive  H+-ATP synthase might contribute to 
retrograde signaling [62, 81] (Fig. 4).
IF1 in cancer
Down-regulation of OXPHOS and the concurrent activa-
tion of aerobic glycolysis is a hallmark of cancer [96] and 
of undifferentiated cells [93, 97], including induced pluri-
potent stem cells (iPSCs) [98]. This metabolic phenotype 
is optimal because it supplies the anabolic intermediates 
needed for proliferation [99–101], and also protects from 
mitochondrial derived ROS [102] and cell death [103]. 
The analysis of large cohorts of different human carcino-
mas indicated that the partial reduction of OXPHOS in 
cancer cells is achieved by down-regulation of the expres-
sion of the catalytic subunit of the  H+-ATP synthase 
Table 1  IF1 expression in 
normal human tissues and in the 
corresponding carcinomas
IF1 expression level is defined as negligible or high as assessed in western blots and/or immunohisto-
chemistries. The relevance of IF1 as biomarker of survival and/or of disease recurrence was assessed in 
Kaplan–Meier plots using the cutoff to define potentially “high-risk” and “low-risk” groups as indicated in 
the indicated references. A high expression level of IF1 stratifies the cohort of patients as indicated. With 
the exception of data in reference [109] that has used mRNA levels, the rest of the studies used protein IF1 
expression data
Organ/tissue Normal Carcinoma Prognosis (High IF1) References
Bladder Negligible High High-risk [107]
Brain (Neurons) High – – [58]
Brain (Glia) Negligible High High-risk [58, 113]
Breast Negligible High Low-risk [83]
Colon Negligible High Low-risk [57, 83, 109]
Endometrium High High – [83]
Kidney High High – [83]
Liver High High High-risk [83, 112]
Lung Negligible High High-risk [83, 108]
Ovary Negligible High – [83]
Stomach High High High-risk/low-risk [83, 109, 111]
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(β-F1-ATPase) [104–106] (for additional references in 
other carcinomas see [99]). More recently, we have shown 
that metabolic rewiring to an enhanced glycolysis is also 
exerted by the overexpression of IF1 in carcinomas [57, 82, 
83] (Table 1). Remarkably, the IF1 present in these carcino-
mas is found in its active dephosphorylated state [81].
Table  1 shows the changes in IF1 expression levels 
observed between normal tissues and the corresponding 
carcinomas. Tissues, such as bladder, breast, colon, lung 
and ovary show negligible expression level of IF1 under 
normal physiological conditions [57, 83, 107] (Table  1). 
However, upon transformation, the carcinomas arising in 
these tissues show very high levels of IF1 (Table 1). Inter-
estingly, whereas in bladder [107] and non-small cell lung 
carcinomas [108] a high expression level of IF1 in the 
tumor predicts a worse patients’ prognosis, a low tumor 
expression of IF1 predicts a worse prognosis in colon and 
breast cancer patients [83]. Consistently, a recent study 
using mRNA expression levels also suggests that a high 
IF1 expression predicts the group of low-risk patients in 
colon cancer [109]. In agreement with a higher metastatic 
potential of breast cancer cells expressing a low level of 
IF1, it has been reported that lymph node metastasis of 
breast cancer patients had a lower expression level of IF1 
when compared to the primary tumors [110]. The reasons 
for the differential behavior of IF1 in cancer progression in 
these carcinomas remain to be investigated.
High energy-demanding human tissues, such as brain, 
liver and kidney, and in addition stomach and endome-
trium, express the highest levels of IF1 under normal physi-
ological conditions [82, 83] (Table  1). For most of these 
tissues (endometrium, kidney, liver and stomach) carcino-
genesis does not promote a relevant increase in the tumor 
expression level of IF1 [83] (Table  1). However, in gas-
tric carcinomas [111] and in hepatocarcinomas [112] the 
tumors that show a higher expression level of IF1 predict 
a worst patient prognosis. However, a recent study using 
mRNA expression levels suggests that a high IF1 expres-
sion predicts the group of low-risk patients [109]. Especial 
consideration deserves the brain which shows very high 
expression levels of IF1 in neurons and negligible in astro-
cytes [58] (Table  1). Interestingly, gliomas show a very 
high expression of IF1 that correlates with a poor patient 
prognosis [113] (Table 1).
The ATPIF1 proximal promoter contains a NFκB 
(nuclear factor kappa B) binding site [83]. It has been 
reported that binding of this transcription factor activates 
ATPIF1 transcription in a feedback loop that promotes 
hepatocarcinogenesis [112]. However, the accumulation of 
IF1 protein in other prevalent human carcinomas (colon, 
lung, breast and ovary) occurs with no relevant changes 
in ATPIF1 mRNA levels [83], suggesting that IF1 expres-
sion is mainly regulated at post-transcriptional levels in 
agreement with findings in other systems [114]. Indeed, 
IF1 has a very short half-life (~2–4  h) [83] and the con-
trol of its turnover is a relevant event in the differentiation 
of human mesenchymal stem cells [93]. The degradation 
of IF1 may involve several mitochondrial proteases [115], 
including serine-proteases [83, 93] and metalloproteases 
[116]. Mouse Ier3 (immediate early response 3) has been 
shown to physically interact with the C-terminal domain of 
IF1 and promote its degradation in a proteasome-independ-
ent way that requires ATP [116].
IF1 overexpression triggers mitochondrial hyperpolari-
zation and the production of superoxide radical [57, 82]. 
Superoxide is rapidly converted into hydrogen peroxide, a 
ROS signaling molecule that activates nuclear programs 
of cell death protection. Mechanistically, ROS-mediated 
signaling induces the canonical NFκB pathway in IF1-over-
expressing cancer cells [57, 83] and in neurons [58] pro-
moting Bcl-xL-guided cell death protection. The nuclear 
signaling pathways activated in response to IF1 overexpres-
sion vary depending on the tissue. In fact, in liver it seems 
that the antioxidant response guided by Nrf2 [nuclear fac-
tor (erythroid-derived 2)-like 2] is crucial in the protec-
tion of hepatocytes from oxidative insults [42]. However, 
we should mention that the metabolic pre-conditioning 
afforded by IF1 overexpression in mouse liver is deleteri-
ous in the context of hepatocarcinogenesis [42], in agree-
ment with recent findings in humans [112].
Since the  H+-ATP synthase is a critical component of 
the PTP, IF1 by potentially regulating the oligomeric state 
of the  H+-ATP synthase, might contribute to upgrade at the 
structural level the threshold to execute cell death [58, 117]. 
However, the overexpression of IF1-H49K mutant in the 
liver of transgenic mice, which promotes the formation of 
 H+-ATP synthase dimers and protects the hepatocytes from 
oxidative insults, indicated that this protection is unrelated 
to differences in PTP opening and regulation [42]. Hence, 
we suggest that the cell death protection afforded by IF1 is 
primarily exerted by signaling mitohormesis [42, 57, 58].
Nucleo-mitochondria communication: 
mitohormesis
There is growing evidence supporting that a mild mito-
chondrial stress can protect the cell from subsequent 
insults, a concept termed mitohormesis [20, 21]. Mito-
hormesis is defined as an adaptive cellular response trig-
gered by a mild mitochondrial malfunctioning that acti-
vates cytoprotective mechanisms to compensate the 
primary defect and results in long-lasting broad metabolic 
and molecular changes. These adaptive changes may finally 
lead to increased lifespan and healthspan. The mitohor-
metic response requires the existence of signaling pathways 
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that sense mitochondrial function and inform the nucleus to 
trigger the adequate cellular programs to compensate stress 
[4]. The signaling pathways emanating from both mito-
chondria and the nucleus have been extensively reviewed 
elsewhere [4, 5].
A stress response pathway with well described cyto-
protective effects is the mitochondrial unfolded protein 
response  (UPRmt). Mitochondrial stress does not only 
involve a compromise in OXPHOS activity, arising from 
defects in mtDNA or poisoning of the ETC, but also by an 
accumulation of unfolded mitochondrial proteins [118]. 
Proteotoxic stresses that exceed the capacity of mitochon-
drial chaperones and proteases induce a transcriptional 
program in the nucleus in an attempt to restore proteo-
stasis and adapt the cellular metabolism to the mitochon-
drial stress. This pathway has been thoroughly described 
in Caenorhabditis elegans [119–122] and is conserved 
in mammals [123–125]. In C. elegans, the sensor protein 
is ATFS-1 (activating transcription factor associated with 
Stress-1), which is normally imported into mitochondria 
and degraded in the matrix. Upon mitochondrial dys-
function, it is accumulated in the cytosol and tends to be 
imported into the nucleus, activating the transcription of 
genes encoding mitochondrial chaperones and proteases, 
proteins of the mitochondrial import machinery and genes 
involved in metabolism and ROS detoxification.
Activation of  UPRmt may extend lifespan. Interestingly, 
knockdown of Mrps5 (mitochondrial ribosomal protein 
S5) and other ribosomal proteins in C. elegans impairs the 
synthesis of mtDNA-encoded ETC subunits and constitu-
tively activates  UPRmt extending lifespan [126] (Fig.  5a). 
In addition, doxycycline—an antibiotic that interferes 
with mitochondrial translation—also causes an imbalance 
between mitochondrial- and nuclear-encoded proteins acti-
vating  UPRmt and extending lifespan in C. elegans and 
muscle fitness in Drosophila melanogaster [127] (Fig. 5a). 
Repletion of  NAD+ levels in aged mice through the supple-
mentation of its precursor nicotinamide riboside promotes 
Fig. 5  Signaling pathways that 
arise from mild mitochondrial 
stresses and contribute to lifes-
pan extension in different model 
organisms. a Activation of the 
mitochondrial unfolded protein 
response  (UPRmt) triggered by 
an imbalance between mito-
chondrial- and nuclear-encoded 
proteins extends longevity. b 
ROS derived from complex 
I (CI) by over-reduction of 
CoQ pool and reverse electron 
transport promote longevity in 
Drosophila melanogaster. Both 
reduction and enhancement of 
respiration in Caenorhabditis 
elegans trigger a ROS signal 
that promotes longevity via 
HIF-1 (hypoxia-inducible factor 
1) or activating antioxidant 
defenses, respectively. c Inhibi-
tion of the  H+-ATP synthase 
by α-ketoglutarate (α-KG) or 
2-hydroxyglutarate (2-HG) 
increases longevity through 
repressing TOR (target of rapa-
mycin) signaling and improving 
proteostasis. Diet composition 
interacts with the knockdown 
(KD) of D. melanogaster 
 H+-ATP synthase subunit d 
(ATPsyn-d) and TOR signaling 
in extending lifespan. Mrps5: 
mitochondrial ribosomal protein 
S5, GR: glucose restriction, 
AMPK: AMP-dependent pro-
tein kinase
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longevity as well as increases the number and regenerative 
potential of muscle stem cells via  UPRmt activation [128]. 
Importantly, inhibiting this pathway by silencing the pro-
hibitin proteins blunts the pro-longevity effects of nicotina-
mide riboside [128]. Therefore, activation of  UPRmt stress 
response improves mitochondrial homeostasis by enhanc-
ing proteotoxicity resistance and protects stem cells from 
senescence.
Increasing evidence suggests that the production of 
low levels of ROS may be protective for the cell, facing 
against the free-radical theory of aging and the long held 
supported protective role of antioxidants [21]. While high 
levels of ROS oxidize and destroy cellular structures [9], 
low amounts of ROS act as signaling molecules that can 
activate gene expression programs [4, 129]. Indeed, moder-
ate ROS induce an antioxidant response mediated by Nrf2 
[130], as well as mitochondrial biogenesis and expression 
of OXPHOS genes [131]. ROS have been reported to inter-
act with two pro-longevity pathways in D. melanogaster, 
the  UPRmt and antagonizing insulin signaling, which exert 
cell autonomous and systemic effects, respectively [132]. 
Interestingly, over-reduction of the coenzyme Q (CoQ) 
pool in D. melanogaster by the expression of NDI1—an 
alternative oxidoreductase that bypasses ETC complex I 
(CI)—enhances the production of superoxide radical and 
extends lifespan [133] (Fig.  5b). This effect is abolished 
when CI is genetically or pharmacologically inhibited sug-
gesting that reverse electron transport may feed CI with 
electrons from CoQ to promote ROS production [133]. 
NDI1 expression, although increases superoxide levels, res-
cues the mitochondrial defects and the reduced lifespan in 
SOD2 and PINK1 knockdown flies, pointing out that the 
site of ROS production is important and might be beneficial 
for cellular homeostasis [133].
Likewise, reduction of mitochondrial activity has been 
related to extended lifespan in C. elegans. Silencing of sub-
units of the ETC complexes I, III and IV or atp-3 (homolog 
of OSCP) during development promotes longevity [134]. 
The effect of a mild inhibition of mitochondrial respira-
tion on the extended lifespan appears to occur via increased 
ROS production, which activates HIF-1 (hypoxia-inducible 
factor 1)-mediated signaling [135] (Fig. 5b). Interestingly, 
treatment of worms with low levels of paraquat increases 
lifespan, while treatment with higher levels of the drug 
actually reduces lifespan, suggesting the existence of a hor-
metic response when the generated ROS are mild [135], in 
agreement with the idea that the amount of generated ROS 
influence lifespan [136].
The metabolic rate, and hence mitochondrial activ-
ity and ROS production have been linked to longevity in 
two controversial theories of aging [137, 138]. In yeast, 
an increased respiration rate is related to extended lifes-
pan [139, 140] and calorie restriction—a well-known 
longevity-promoting intervention—increases mitochon-
drial respiration [141]. Similarly, calorie restriction extends 
lifespan in C. elegans [142] and in D. melanogaster [143] 
by inducing respiration. In case of the worm, promotion of 
mitochondrial respiration requires the activation of AMPK 
(AMP-dependent protein kinase) and also increases ROS 
production, triggering a cytoprotective antioxidant hor-
metic response [142] (Fig.  5b). Blunting the yeast TOR 
signaling pathway either by tor1 gene deletion or rapamy-
cin treatment enhances the respiratory capacity and chemi-
osmotic coupling, thereby increasing mitochondrial mem-
brane potential and ROS production [144]. Importantly, 
uncoupling of respiration in the tor1Δ mutants abolishes 
the pro-longevity effects of TOR inhibition, while trig-
gering mitochondrial ROS production in wild-type strains 
with menadione is sufficient to extend lifespan [144]. 
In general, inhibition of mTOR signaling extends lifes-
pan and healthspan in several organisms including mam-
mals, and is believed as a main effector of dietary restric-
tion [145]. Interventions that promote longevity, such as 
calorie restriction, mild mitochondrial dysfunction and 
impaired insulin/IGF1-signaling have been related to ROS-
mediated signaling [21]. Regarding the link between mito-
chondrial activity and lifespan, different results have also 
been reported in mouse. For instance, in the conditional 
knockout model of the insulin receptor in adipose tissue 
an upregulated mitochondrial biogenesis and function cor-
relates with an extended longevity apparently unrelated 
to an enhanced production of ROS [146]. In contrast, the 
knockout model of the ETC complex IV assembly factor 
Surf1 (surfeit locus protein 1)—which shows a reduction 
in cytochrome oxidase activity—is associated with a longer 
median lifespan and the induction of mitochondrial stress 
pathways comprising  UPRmt, Nrf2 and mitochondrial bio-
genesis [147, 148].
Overall, and in agreement with previous suggestions 
[136], major thoughts that emerge from the implication of 
ROS in lifespan extension are that the amount being pro-
duced, the species generated, the site of production and the 
subsequent nuclear response determines ROS influence in 
lifespan extension.
Besides ROS, mitochondria also produce metabolites 
that can signal to the rest of the cell [4]. C. elegans respira-
tory mutants with extended lifespan generate high amounts 
of α-ketoacids [149], molecules structurally related to 
α-ketoglutarate, a metabolite that promotes longevity [59]. 
α-ketoglutarate binds to the α and β subunits of the  H+-ATP 
synthase and inhibits the complex. By reducing ATP lev-
els, α-ketoglutarate reduces TOR signaling, promoting 
autophagy and proteostasis that ultimately leads to lifespan 
extension (Fig.  5c) [59]. 2-hydroxyglutarate, an analog of 
α-ketoglutarate, also inhibits the  H+-ATP synthase in C. 
elegans, reducing TOR signaling and extending lifespan 
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[150] (Fig. 5c). Interestingly, treatment of wild-type C. ele-
gans with the metabolites generated and extruded by res-
piratory mutant worms is sufficient to extend lifespan and 
this occurs at least by HIF-1-mediated signaling [149].
The mitochondrial  H+-ATP synthase itself has been 
linked to lifespan because several of its subunits [atp-3, 
atp-4, atp-5 and asb-2, which, respectively, encode OSCP, 
F6, d and b subunit homologs and constitute the peripheral 
stalk of the complex (Fig.  1a)] were identified in RNAi 
screens for genes promoting longevity in C. elegans [134, 
151]. Interestingly, a twofold upregulation of the D. mela-
nogaster IF1 homolog (CG34423) has been reported in a 
fly model with extended lifespan [152]. Likewise, silenc-
ing of D. melanogaster ATPsyn-d (ATP synthase d subu-
nit) reduces TOR signaling and activates genes involved 
in proteostasis and antioxidant defense, thus promoting a 
stress resistance phenotype that ultimately leads to lifespan 
extension [153] (Fig.  5c). Interestingly, this knockdown 
only promotes longevity when flies are fed with low carbo-
hydrate-to-protein ratio, pointing out that longevity arises 
from an interaction between diet and the  H+-ATP synthase 
[153]. This effect does not seem to be due to electron flux 
by different supercomplexes [154], because no changes in 
supercomplex assembly have been reported [153].
IF1 overexpression inhibits the  H+-ATP synthase activ-
ity and reprograms energy metabolism to an enhanced gly-
colysis in cell lines [57] and in in vivo models [42, 58]. The 
IF1-mediated inhibition of the  H+-ATP synthase represents 
a mild mitochondrial dysfunction that confers cytoprotec-
tion through the activation of cell survival, antioxidant 
and repair pathways. In colon cancer cells, IF1 triggers a 
mild ROS signal that promotes cell survival through NFκB 
signaling (Fig. 6) [57]. In the in vivo mouse model overex-
pressing hIF1-H49K in the liver, the transgene triggers the 
activation of the stress kinase AMPK [42]. In response to 
an oxidative insult, the transgenic mice deploy an increased 
antioxidant defense guided by Nrf2 when compared to 
controls, thus promoting hepatocyte survival [42] (Fig. 6). 
Likewise, the overexpression in  vivo of hIF1-H49K in 
neurons triggers the activation of AMPK and affords neu-
roprotection against excitotoxic cell death through NFκB-
mediated signaling and Akt (AKT serine/threonine kinase)/
p70S6K (ribosomal protein S6 kinase, 70 kDa) and PARP 
(poly(ADP-ribose) polymerase) repair pathways [58] 
(Fig. 6). In these mouse models, the overexpression of IF1 
is associated with a mild ROS signal as assessed by the car-
bonylation of cellular proteins and the concurrent activation 
of AMPK [42, 57, 58] that might reduce mTOR signaling. 
Hence, we speculate that mitochondrial retrograde signal-
ing by limiting cellular ATP availability and enhancing the 
production of ROS through the IF1-mediated inhibition of 
the  H+-ATP synthase contribute to preserve tissue homeo-
stasis and healthy lifespan.
Concluding remarks
The  H+-ATP synthase is a crucial hub that integrates energy 
metabolism and intracellular signaling pathways that con-
tribute to decide cellular fate. Regulation of the activity of 
the  H+-ATP synthase is exerted by its physiological inhibi-
tor IF1. IF1 phosphorylation/ dephosphorylation is regu-
lated during the cell cycle, in hypoxia, by nutrient availabil-
ity and upon an increase in energy demand of the tissue. 
Phosphorylation of IF1 by the activity of a mitochondrial 
cAMP-dependent protein kinase prevents the interaction 
of the inhibitor with the enzyme allowing ATP synthesis 
in energized mitochondria or ATP hydrolysis in case that 
mitochondria become de-energized. When IF1 is bound 
to the enzyme favors the generation of ROS from the ETC 
Fig. 6  Signaling pathways modulated by IF1 that confer cell death 
protection. IF1-mediated inhibition of the  H+-ATP synthase triggers 
metabolic reprogramming to an enhanced glycolysis and the activa-
tion of AMPK (AMP-dependent protein kinase). IF1 inhibition of the 
synthase also increases ROS production and the ROS-dependent acti-
vation of NFκB (nuclear factor kappa B). ROS might also mediate the 
enhanced Nrf2 [nuclear factor (erythroid-derived 2)-like 2]-guided 
response that prevents oxidative damage. In neurons, IF1 inhibi-
tion of the  H+-ATP synthase activates Akt (AKT serine/threonine 
kinase), p70S6K (ribosomal protein S6 kinase, 70  kDa) and PARP 
(poly(ADP-ribose) polymerase) survival and repair pathways
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triggering a nuclear response that promotes cell survival by 
different mechanisms. The outcome of the IF1-mediated 
signaling depends on the genetic background of the cell. 
In normal post-mitotic cells, it allows withstanding subse-
quent detrimental stresses favoring normal tissue function. 
In malignant cells, IF1 propitiates the acquisition of can-
cer traits, such as increased proliferation, evasion from cell 
death and invasion capacity. Actually, IF1 is overexpressed 
in most prevalent human carcinomas being found essen-
tially in the dephosphorylated state, and hence as an active 
inhibitor of the  H+-ATP synthase. In mouse heart under 
basal conditions, IF1 is present both in the phosphorylated 
and dephosphorylated states. β-adrenergic stimulation trig-
gers the phosphorylation of IF1 and the activation of ATP 
production within mitochondria, indicating that there is a 
fraction of  H+-ATP synthase in the tissue that is inactive 
in the handling of ATP but might be active as a “light-
house” that signals mitohormetic processes by regulating 
the generation of a mild ROS signal. The identification of 
the kinase and phosphatase that regulate the activity of IF1, 
as well as the quantification of dephosphorylated IF1 that is 
present under basal conditions in different tissues, will con-
tribute to delineate the relevance of the  H+-ATP synthase 
in tissue homeostasis. Inhibition of the  H+-ATP synthase 
by metabolites and perhaps by other mechanisms contrib-
utes to extending lifespan in different organisms through 
reduced TOR signaling leading to increased proteostasis 
and reduced oxidative damage. ROS signaling appears to 
be a common pathway in lifespan extension. Deciphering 
the precise molecular pathways that are modulated by the 
 H+-ATP synthase and contribute to tissue homeostasis and 
lifespan extension will be of great interest to develop new 
approaches for therapies in age-related diseases. The gen-
eration of mouse models with tissue-specific and regulated 
expression of IF1 and conditional IF1-knockout models 
will contribute to unveil the functional role of the  H+-ATP 
synthase in cellular physiology and pathophysiology.
Acknowledgements The authors gratefully acknowledge the work 
and ideas of many colleagues and collaborators, especially to Drs. 
María Sánchez-Aragó and Laura Formentini and to the excellent 
technical support provided by M. Chamorro and C. Núñez de Arenas 
over all these years. Work in the authors’ laboratory is supported by 
grants from the Ministerio de Economía y Competitividad (MINECO) 
(SAF2013-41945-R), Centro de Investigación Biomédica en Red de 
Enfermedades Raras (CIBERER) (CB06/07/0017), Fundación Ramón 
Areces (FRA) and Comunidad de Madrid (S2011/BMD-2402), Spain. 
P.B.E.M. and C.N.T. hold a predoctoral fellowship from Fundación 
La Caixa (Obra Social La Caixa) and FPI-MINECO and Fondo Social 
Europeo, respectively. The CBMSO receives an institutional grant 
from FRA. We apologize to authors whose work has not been cited 
owing to space limitations.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996) Induc-
tion of apoptotic program in cell-free extracts: requirement for 
dATP and cytochrome c. Cell 86:147–157
 2. Susin SA, Zamzami N, Kroemer G (1998) Mitochondria as 
regulators of apoptosis: doubt no more. Biochim Biophys Acta 
1366:151–165
 3. Bernardi P, Rasola A, Forte M, Lippe G (2015) The mito-
chondrial permeability transition pore: channel formation by 
F-ATP synthase, integration in signal transduction, and role 
in pathophysiology. Physiol Rev 95:1111–1155. doi:10.1152/
physrev.00001.2015
 4. Chandel NS (2015) Evolution of mitochondria as signal-
ing organelles. Cell Metab 22:204–206. doi:10.1016/j.
cmet.2015.05.013
 5. Quiros PM, Mottis A, Auwerx J (2016) Mitonuclear com-
munication in homeostasis and stress. Nat Rev Mol Cell Biol 
17:213–226. doi:10.1038/nrm.2016.23
 6. Lopez-Crisosto C, Bravo-Sagua R, Rodriguez-Pena M, Mera 
C, Castro PF, Quest AF, Rothermel BA, Cifuentes M, Lavan-
dero S (2015) ER-to-mitochondria miscommunication and 
metabolic diseases. Biochim Biophys Acta 1852:2096–2105. 
doi:10.1016/j.bbadis.2015.07.011
 7. Sena LA, Chandel NS (2012) Physiological roles of mito-
chondrial reactive oxygen species. Mol Cell 48:158–167. 
doi:10.1016/j.molcel.2012.09.025S1097-2765(12)00825-8 [pii]
 8. Glancy B, Balaban RS (2012) Role of mitochondrial Ca2 + in 
the regulation of cellular energetics. BioChemistry 51:2959–
2973. doi:10.1021/bi2018909
 9. Martinez-Reyes I, Cuezva JM (2014) The H(+)-ATP synthase: a 
gate to ROS-mediated cell death or cell survival. Biochim Bio-
phys Acta 1837:1099–1112. doi:10.1016/j.bbabio.2014.03.010
 10. Kaludercic N, Giorgio V (2016) The dual function of reactive 
oxygen/nitrogen species in bioenergetics and cell death: the 
role of ATP synthase. Oxid Med Cell Longev 2016:3869610. 
doi:10.1155/2016/3869610
 11. Weinberg SE, Sena LA, Chandel NS (2015) Mitochondria 
in the regulation of innate and adaptive immunity. Immunity 
42:406–417. doi:10.1016/j.immuni.2015.02.002
 12. Shi L, Tu BP (2015) Acetyl-CoA and the regulation of metab-
olism: mechanisms and consequences. Curr Opin Cell Biol 
33:125–131. doi:10.1016/j.ceb.2015.02.003
 13. West AP, Khoury-Hanold W, Staron M, Tal MC, Pineda CM, 
Lang SM, Bestwick M, Duguay BA, Raimundo N, MacDuff 
DA, Kaech SM, Smiley JR, Means RE, Iwasaki A, Shadel 
GS (2015) Mitochondrial DNA stress primes the antiviral 
innate immune response. Nature 520:553–557. doi:10.1038/
nature14156
 14. D’Autreaux B, Toledano MB (2007) ROS as signalling mole-
cules: mechanisms that generate specificity in ROS homeosta-
sis. Nat Rev Mol Cell Biol 8:813–824. doi:10.1038/nrm2256
 15. Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterth-
wait AC, Reed JC (2003) Humanin peptide suppresses apop-
tosis by interfering with Bax activation. Nature 423:456–461. 
doi:10.1038/nature01627
 16. Pernas L, Scorrano L (2016) Mito-morphosis: mitochondrial 
fusion, fission, and cristae remodeling as key mediators of 
 P. B. Esparza-Moltó et al.
1 3
cellular function. Annu Rev Physiol 78:505–531. doi:10.1146/
annurev-physiol-021115-105011
 17. Youle RJ, Narendra DP (2011) Mechanisms of mitophagy. 
Nat Rev Mol Cell Biol 12:9–14
 18. Labbe K, Murley A, Nunnari J (2014) Determinants and func-
tions of mitochondrial behavior. Annu Rev Cell Dev Biol 
30:357–391. doi:10.1146/annurev-cellbio-101011-155756
 19. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere 
JL, Petit PX, Kroemer G (1995) Reduction in mitochondrial 
potential constitutes an early irreversible step of programmed 
lymphocyte death in vivo. J Exp Med 181:1661–1672
 20. Yun J, Finkel T (2014) Mitohormesis. Cell Metab 19:757–
766. doi:10.1016/j.cmet.2014.01.011
 21. Ristow M (2014) Unraveling the truth about antioxidants: 
mitohormesis explains ROS-induced health benefits. Nat Med 
20:709–711. doi:10.1038/nm.3624
 22. Enriquez JA (2016) Supramolecular organization of respira-
tory complexes. Annu Rev Physiol 78:533–561. doi:10.1146/
annurev-physiol-021115-105031
 23. Cogliati S, Enriquez JA, Scorrano L (2016) Mitochondrial 
cristae: where beauty meets functionality. Trends Biochem 
Sci 41:261–273. doi:10.1016/j.tibs.2016.01.001
 24. Wittig I, Schagger H (2009) Supramolecular organization of 
ATP synthase and respiratory chain in mitochondrial mem-
branes. Biochim Biophys Acta 1787:672–680. doi:10.1016/j.
bbabio.2008.12.016
 25. Walker JE (2013) The ATP synthase: the understood, the 
uncertain and the unknown. Biochem Soc Trans 41:1–16. 
doi:10.1042/BST20110773
 26. Boyer PD (1997) The ATP synthase. A splendid molecular 
machine. Annu Rev Biochem 66:717–749
 27. Boveris A, Chance B (1973) The mitochondrial generation 
of hydrogen peroxide. General properties and effect of hyper-
baric oxygen. Biochem J 134:707–716
 28. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, 
Miwa S, Pakay JL, Parker N (2004) Mitochondrial superox-
ide: production, biological effects, and activation of uncou-
pling proteins. Free Radic Biol Med 37:755–767
 29. Lee J, Ding S, Walpole TB, Holding AN, Montgomery MG, 
Fearnley IM, Walker JE (2015) Organization of subunits in 
the membrane domain of the bovine F-ATPase revealed 
by covalent cross-linking. J Biol Chem 290:13308–13320. 
doi:10.1074/jbc.M115.645283
 30. Saita E, Suzuki T, Kinosita K Jr, Yoshida M (2015) Simple 
mechanism whereby the F1-ATPase motor rotates with near-
perfect chemomechanical energy conversion. Proc Natl Acad 
Sci USA 112:9626–9631. doi:10.1073/pnas.1422885112
 31. Zeng X, Neupert W, Tzagoloff A (2007) The metalloprotease 
encoded by ATP23 has a dual function in processing and 
assembly of subunit 6 of mitochondrial ATPase. Mol Biol 
Cell 18:617–626. doi:10.1091/mbc.E06-09-0801
 32. Rak M, Gokova S, Tzagoloff A (2011) Modular assembly 
of yeast mitochondrial ATP synthase. EMBO J 30:920–930. 
doi:10.1038/emboj.2010.364
 33. Lytovchenko O, Naumenko N, Oeljeklaus S, Schmidt B, von 
der Malsburg K, Deckers M, Warscheid B, van der Laan M, 
Rehling P (2014) The INA complex facilitates assembly of 
the peripheral stalk of the mitochondrial F1Fo-ATP synthase. 
EMBO J 33:1624–1638. doi:10.15252/embj.201488076
 34. Fujikawa M, Sugawara K, Tanabe T, Yoshida M (2015) 
Assembly of human mitochondrial ATP synthase through two 
separate intermediates, F1-c-ring and b-e-g complex. FEBS 
Lett 589:2707–2712. doi:10.1016/j.febslet.2015.08.006
 35. Ohsakaya S, Fujikawa M, Hisabori T, Yoshida M (2011) 
Knockdown of DAPIT (diabetes-associated protein in 
insulin-sensitive tissue) results in loss of ATP synthase in 
mitochondria. J Biol Chem 286:20292–20296. doi:10.1074/
jbc.M110.198523
 36. Fujikawa M, Ohsakaya S, Sugawara K, Yoshida M (2014) Pop-
ulation of ATP synthase molecules in mitochondria is limited 
by available 6.8-kDa proteolipid protein (MLQ). Genes Cells 
19:153–160. doi:10.1111/gtc.12121
 37. Davies KM, Strauss M, Daum B, Kief JH, Osiewacz HD, 
Rycovska A, Zickermann V, Kuhlbrandt W (2011) Macromo-
lecular organization of ATP synthase and complex I in whole 
mitochondria. Proc Natl Acad Sci USA 108:14121–14126
 38. Buzhynskyy N, Sens P, Prima V, Sturgis JN, Scheuring S 
(2007) Rows of ATP synthase dimers in native mitochondrial 
inner membranes. Biophys J 93:2870–2876. doi:10.1529/
biophysj.107.109728
 39. Strauss M, Hofhaus G, Schroder RR, Kuhlbrandt W (2008) 
Dimer ribbons of ATP synthase shape the inner mitochondrial 
membrane. EMBO J 27:1154–1160
 40. Paumard P, Arselin G, Vaillier J, Chaignepain S, Bathany 
K, Schmitter JM, Brethes D, Velours J (2002) Two ATP syn-
thases can be linked through subunits i in the inner mitochon-
drial membrane of Saccharomyces cerevisiae. BioChemistry 
41:10390–10396
 41. Hahn A, Parey K, Bublitz M, Mills DJ, Zickermann V, Vonck 
J, Kuhlbrandt W, Meier T (2016) Structure of a complete ATP 
synthase dimer reveals the molecular basis of inner mito-
chondrial membrane morphology. Mol Cell 63:445–456. 
doi:10.1016/j.molcel.2016.05.037
 42. Santacatterina F, Sanchez-Cenizo L, Formentini L, Mobasher 
MA, Casas E, Rueda CB, Martinez-Reyes I, Nunez de Arenas C, 
Garcia-Bermudez J, Zapata JM, Sanchez-Arago M, Satrustegui 
J, Valverde AM, Cuezva JM (2016) Down-regulation of oxida-
tive phosphorylation in the liver by expression of the ATPase 
inhibitory factor 1 induces a tumor-promoter metabolic state. 
Oncotarget 7:490–508. doi:10.18632/oncotarget.6357
 43. Gordon-Smith DJ, Carbajo RJ, Yang JC, Videler H, Runswick 
MJ, Walker JE, Neuhaus D (2001) Solution structure of a C-ter-
minal coiled-coil domain from bovine IF(1): the inhibitor pro-
tein of F(1) ATPase. J Mol Biol 308:325–339
 44. Cabezon E, Montgomery MG, Leslie AG, Walker JE (2003) 
The structure of bovine F1-ATPase in complex with its regu-
latory protein IF1. Nat Struct Biol 10:744–750. doi:10.1038/
nsb966nsb966 [pii]
 45. Garcia JJ, Morales-Rios E, Cortes-Hernandez P, Rodriguez-
Zavala JS (2006) The inhibitor protein (IF1) promotes dimeri-
zation of the mitochondrial F1F0-ATP synthase. BioChemistry 
45:12695–12703. doi:10.1021/bi060339j
 46. Campanella M, Casswell E, Chong S, Farah Z, Wieckowski 
MR, Abramov AY, Tinker A, Duchen MR (2008) Regulation 
of mitochondrial structure and function by the F1Fo-ATPase 
inhibitor protein, IF1. Cell Metab 8:13–25. doi:10.1016/j.
cmet.2008.06.001
 47. Cabezon E, Arechaga I, Jonathan P, Butler G, Walker JE (2000) 
Dimerization of bovine F1-ATPase by binding the inhibitor pro-
tein, IF1. J Biol Chem 275:28353–28355
 48. Dienhart M, Pfeiffer K, Schagger H, Stuart RA (2002) Forma-
tion of the yeast F1F0-ATP synthase dimeric complex does 
not require the ATPase inhibitor protein, Inh1. J Biol Chem 
277:39289–39295
 49. Tomasetig L, Di Pancrazio F, Harris DA, Mavelli I, Lippe G 
(2002) Dimerization of F0F1ATP synthase from bovine heart is 
independent from the binding of the inhibitor protein IF1. Bio-
chim Biophys Acta 1556:133–141
 50. Fujikawa M, Imamura H, Nakamura J, Yoshida M (2012) 
Assessing the actual contribution of IF1, an inhibitor of mito-
chondrial FoF1, to ATP homeostasis, cell growth, mitochondrial 
morphology and cell viability. J Biol Chem 287:18781–18787
Regulation of the  H+-ATP synthase by IF1: a role in mitohormesis 
1 3
 51. Minauro-Sanmiguel F, Wilkens S, Garcia JJ (2005) Struc-
ture of dimeric mitochondrial ATP synthase: novel F0 bridg-
ing features and the structural basis of mitochondrial cris-
tae biogenesis. Proc Natl Acad Sci USA 102:12356–12358. 
doi:10.1073/pnas.0503893102
 52. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari 
F, Forte M, Glick GD, Petronilli V, Zoratti M, Szabo I, Lippe 
G, Bernardi P (2013) Dimers of mitochondrial ATP synthase 
form the permeability transition pore. Proc Natl Acad Sci 
USA 110:5887–5892. doi:10.1073/pnas.1217823110
 53. Carraro M, Giorgio V, Sileikyte J, Sartori G, Forte M, Lippe 
G, Zoratti M, Szabo I, Bernardi P (2014) Channel forma-
tion by yeast F-ATP synthase and the role of dimerization 
in the mitochondrial permeability transition. J Biol Chem 
289:15980–15985. doi:10.1074/jbc.C114.559633
 54. von Stockum S, Giorgio V, Trevisan E, Lippe G, Glick GD, 
Forte MA, Da-Re C, Checchetto V, Mazzotta G, Costa R, 
Szabo I, Bernardi P (2015) F-ATPase of Drosophila mela-
nogaster forms 53-picosiemen (53-pS) channels responsible 
for mitochondrial Ca2+-induced Ca2+ release. J Biol Chem 
290:4537–4544. doi:10.1074/jbc.C114.629766
 55. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebiedzinska 
M, Marchi S, Patergnani S, Rimessi A, Suski JM, Wojtala A, 
Wieckowski MR, Kroemer G, Galluzzi L, Pinton P (2013) 
Role of the c subunit of the FO ATP synthase in mito-
chondrial permeability transition. Cell Cycle 12:674–683. 
doi:10.4161/cc.23599
 56. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, 
Licznerski P, Li H, Nabili P, Hockensmith K, Graham M, 
Porter GA Jr, Jonas EA (2014) An uncoupling channel within 
the c-subunit ring of the F1FO ATP synthase is the mitochon-
drial permeability transition pore. Proc Natl Acad Sci USA 
111:10580–10585. doi:10.1073/pnas.1401591111
 57. Formentini L, Sánchez-Aragó M, Sánchez-Cenizo L, Cuezva 
JM (2012) The mitochondrial ATPase inhibitory factor 1 
(IF1) triggers a ROS-mediated retrograde pro-survival and 
proliferative response. Mol Cell 45:731–742
 58. Formentini L, Pereira MP, Sanchez-Cenizo L, Santacatte-
rina F, Lucas JJ, Navarro C, Martinez-Serrano A, Cuezva JM 
(2014) In vivo inhibition of the mitochondrial H+-ATP syn-
thase in neurons promotes metabolic preconditioning. EMBO 
J 33:762–778. doi:10.1002/embj.201386392
 59. Chin RM, Fu X, Pai MY, Vergnes L, Hwang H, Deng G, Diep 
S, Lomenick B, Meli VS, Monsalve GC, Hu E, Whelan SA, 
Wang JX, Jung G, Solis GM, Fazlollahi F, Kaweeteerawat C, 
Quach A, Nili M, Krall AS, Godwin HA, Chang HR, Faull 
KF, Guo F, Jiang M, Trauger SA, Saghatelian A, Braas D, 
Christofk HR, Clarke CF, Teitell MA, Petrascheck M, Reue 
K, Jung ME, Frand AR, Huang J (2014) The metabolite alpha-
ketoglutarate extends lifespan by inhibiting ATP synthase and 
TOR. Nature 510:397–401. doi:10.1038/nature13264
 60. Das AM, Harris DA (1990) Control of mitochondrial ATP 
synthase in heart cells: inactive to active transitions caused 
by beating or positive inotropic agents. Cardiovasc Res 
24:411–417
 61. Das AM (2003) Regulation of the mitochondrial ATP-synthase 
in health and disease. Mol Genet Metab 79:71–82
 62. Garcia-Bermudez J, Cuezva JM (2016) The ATPase Inhibi-
tory Factor 1 (IF1): a master regulator of energy metabolism 
and of cell survival. Biochim Biophys Acta 1857:1167–1182. 
doi:10.1016/j.bbabio.2016.02.004
 63. Rizzuto R, De Stefani D, Raffaello A, Mammucari C (2012) 
Mitochondria as sensors and regulators of calcium signalling. 
Nat Rev Mol Cell Biol 13:566–578. doi:10.1038/nrm3412
 64. Llorente-Folch I, Rueda CB, Pardo B, Szabadkai G, Duchen 
MR, Satrustegui J (2015) The regulation of neuronal 
mitochondrial metabolism by calcium. J Physiol 593:3447–
3462. doi:10.1113/JP270254
 65. Boerries M, Most P, Gledhill JR, Walker JE, Katus HA, Koch 
WJ, Aebi U, Schoenenberger CA (2007) Ca2+ -dependent 
interaction of S100A1 with F1-ATPase leads to an increased 
ATP content in cardiomyocytes. Mol Cell Biol 27:4365–4373. 
doi:10.1128/MCB.02045-06
 66. Yamada EW, Huzel NJ (1988) The calcium-binding ATPase 
inhibitor protein from bovine heart mitochondria. Purification 
and properties. J Biol Chem 263:11498–11503
 67. Kornmann B, Currie E, Collins SR, Schuldiner M, Nunnari 
J, Weissman JS, Walter P (2009) An ER-mitochondria tether-
ing complex revealed by a synthetic biology screen. Science 
325:477–481. doi:10.1126/science.1175088
 68. Michel AH, Kornmann B (2012) The ERMES complex and 
ER-mitochondria connections. Biochem Soc Trans 40:445–450. 
doi:10.1042/BST20110758
 69. Mishra P, Chan DC (2014) Mitochondrial dynamics and inher-
itance during cell division, development and disease. Nat Rev 
Mol Cell Biol 15:634–646. doi:10.1038/nrm3877
 70. Kontro H, Hulmi JJ, Rahkila P, Kainulainen H (2012) Cellular 
and tissue expression of DAPIT, a phylogenetically conserved 
peptide. Eur J Histochem 56:e18. doi:10.4081/ejh.2012.18
 71. Kontro H, Cannino G, Rustin P, Dufour E, Kainulainen H 
(2015) DAPIT Over-Expression Modulates Glucose Metab-
olism and Cell Behaviour in HEK293T Cells. PLoS One 
10:e0131990. doi:10.1371/journal.pone.0131990
 72. Alavian KN, Li H, Collis L, Bonanni L, Zeng L, Sacchetti S, 
Lazrove E, Nabili P, Flaherty B, Graham M, Chen Y, Messerli 
SM, Mariggio MA, Rahner C, McNay E, Shore GC, Smith PJ, 
Hardwick JM, Jonas EA (2011) Bcl-x(L) regulates metabolic 
efficiency of neurons through interaction with the mitochondrial 
F(1)F(O) ATP synthase. Nat Cell Biol 13:1224–1233
 73. Kioka H, Kato H, Fujikawa M, Tsukamoto O, Suzuki T, Ima-
mura H, Nakano A, Higo S, Yamazaki S, Matsuzaki T, Takafuji 
K, Asanuma H, Asakura M, Minamino T, Shintani Y, Yoshida 
M, Noji H, Kitakaze M, Komuro I, Asano Y, Takashima S 
(2014) Evaluation of intramitochondrial ATP levels identi-
fies G0/G1 switch gene 2 as a positive regulator of oxidative 
phosphorylation. Proc Natl Acad Sci USA 111:273–278. 
doi:10.1073/pnas.1318547111
 74. Pullman ME, Monroy GC (1963) A naturally occurring inhibi-
tor of mitochondrial adenosine triphosphatase. J Biol Chem 
238:3762–3769
 75. Cabezon E, Butler PJ, Runswick MJ, Carbajo RJ, Walker 
JE (2002) Homologous and heterologous inhibitory effects 
of ATPase inhibitor proteins on F-ATPases. J Biol Chem 
277:41334–41341. doi:10.1074/jbc.M207169200
 76. Cabezon E, Runswick MJ, Leslie AG, Walker JE (2001) The 
structure of bovine IF(1), the regulatory subunit of mitochon-
drial F-ATPase. Embo J 20:6990–6996
 77. Wright PE, Dyson HJ (2015) Intrinsically disordered proteins 
in cellular signalling and regulation. Nat Rev Mol Cell Biol 
16:18–29. doi:10.1038/nrm3920
 78. Gledhill JR, Montgomery MG, Leslie AG, Walker JE 
(2007) How the regulatory protein, IF(1), inhibits F(1)-
ATPase from bovine mitochondria. Proc Natl Acad Sci USA 
104:15671–15676
 79. Bason JV, Montgomery MG, Leslie AG, Walker JE (2014) 
Pathway of binding of the intrinsically disordered mitochon-
drial inhibitor protein to F1-ATPase. Proc Natl Acad Sci USA 
111:11305–11310. doi:10.1073/pnas.1411560111
 80. Suzuki T, Tanaka K, Wakabayashi C, Saita E, Yoshida M 
(2014) Chemomechanical coupling of human mitochondrial 
F1-ATPase motor. Nat Chem Biol 10:930–936. doi:10.1038/
nchembio 0.1635
 P. B. Esparza-Moltó et al.
1 3
 81. Garcia-Bermudez J, Sanchez-Arago M, Soldevilla B, Del Arco 
A, Nuevo-Tapioles C, Cuezva JM (2015) PKA phosphorylates 
the ATPase inhibitory factor 1 and inactivates its capacity to 
bind and inhibit the mitochondrial H-ATP synthase. Cell Rep 
12:2143–2155. doi:10.1016/j.celrep.2015.08.052
 82. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-
Huerta P, Sanchez-Arago M, Cuezva JM (2010) Up-regulation 
of the ATPase inhibitory factor 1 (IF1) of the mitochondrial 
H+-ATP synthase in human tumors mediates the metabolic 
shift of cancer cells to a Warburg phenotype. J Biol Chem 
285:25308–25313. doi:10.1074/jbc.M110.146480
 83. Sanchez-Arago M, Formentini L, Martinez-Reyes I, Garcia-
Bermudez J, Santacatterina F, Sanchez-Cenizo L, Willers IM, 
Aldea M, Najera L, Juarranz A, Lopez EC, Clofent J, Navarro 
C, Espinosa E, Cuezva JM (2013) Expression, regulation and 
clinical relevance of the ATPase inhibitory factor 1 in human 
cancers. Oncogenesis 2:e46. doi:10.1038/oncsis.2013.9
 84. Zanotti F, Gnoni A, Mangiullo R, Papa S (2009) Effect of the 
ATPase inhibitor protein IF1 on H + translocation in the mito-
chondrial ATP synthase complex. Biochem Biophys Res Com-
mun 384:43–48
 85. Cabezon E, Butler PJ, Runswick MJ, Walker JE (2000) Modu-
lation of the oligomerization state of the bovine F1-ATPase 
inhibitor protein, IF1, by pH. J Biol Chem 275:25460–25464. 
doi:10.1074/jbc.M003859200
 86. Zhang F, Zhang L, Qi Y, Xu H (2016) Mitochondrial cAMP 
signaling. Cell Mol Life Sci. doi:10.1007/s00018-016-2282-2
 87. Acin-Perez R, Salazar E, Kamenetsky M, Buck J, Levin LR, 
Manfredi G (2009) Cyclic AMP produced inside mitochondria 
regulates oxidative phosphorylation. Cell Metab 9:265–276. 
doi:10.1016/j.cmet.2009.01.012S1550-4131(09)00037-0 [pii]
 88. Acin-Perez R, Gatti DL, Bai Y, Manfredi G (2011) Protein 
phosphorylation and prevention of cytochrome oxidase inhibi-
tion by ATP: coupled mechanisms of energy metabolism regu-
lation. Cell Metab 13:712–719. doi:10.1016/j.cmet.2011.03.024
 89. Di Benedetto G, Scalzotto E, Mongillo M, Pozzan T (2013) 
Mitochondrial Ca(2)(+) uptake induces cyclic AMP generation 
in the matrix and modulates organelle ATP levels. Cell Metab 
17:965–975. doi:10.1016/j.cmet.2013.05.003
 90. Sugawara K, Fujikawa M, Yoshida M (2013) Screening of pro-
tein kinase inhibitors and knockdown experiments identified 
four kinases that affect mitochondrial ATP synthesis activity. 
FEBS Lett 587:3843–3847. doi:10.1016/j.febslet.2013.10.012
 91. Di Benedetto G, Pendin D, Greotti E, Pizzo P, Pozzan T 
(2014) Ca2 + and cAMP cross-talk in mitochondria. J Physiol 
592:305–312. doi:10.1113/jphysiol.2013.259135
 92. Lefkimmiatis K, Zaccolo M (2014) cAMP signaling in sub-
cellular compartments. Pharmacol Ther 143:295–304. 
doi:10.1016/j.pharmthera.2014.03.008
 93. Sanchez-Arago M, Garcia-Bermudez J, Martinez-Reyes I, San-
tacatterina F, Cuezva JM (2013) Degradation of IF1 controls 
energy metabolism during osteogenic differentiation of stem 
cells. EMBO Rep 14:638–644. doi:10.1038/embor.2013.72
 94. Zanotti F, Raho G, Gaballo A, Papa S (2004) Inhibitory 
and anchoring domains in the ATPase inhibitor protein IF1 
of bovine heart mitochondrial ATP synthase. J Bioenerg 
Biomembr 36:447–457. doi:10.1023/B:JOBB.0000047327.681
73.9b
 95. Lopez-Mediavilla C, Vigny H, Godinot C (1993) Docking 
the mitochondrial inhibitor protein IF1 to a membrane recep-
tor different from the F1-ATPase beta subunit. Eur J Biochem 
215:487–496
 96. Warburg O (1956) On respiratory impairment in cancer cells. 
Science 124:269–270
 97. Kondoh H, Lleonart ME, Nakashima Y, Yokode M, Tanaka 
M, Bernard D, Gil J, Beach D (2007) A high glycolytic flux 
supports the proliferative potential of murine embryonic 
stem cells. Antioxid Redox Signal 9:293–299. doi:10.1089/
ars.2007.9.ft-14
 98. Xu X, Duan S, Yi F, Ocampo A, Liu GH, Izpisua Belmonte JC 
(2013) Mitochondrial regulation in pluripotent stem cells. Cell 
Metab 18:325–332. doi:10.1016/j.cmet.2013.06.005
 99. Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea 
M, Sanchez-Arago M (2009) The tumor suppressor function 
of mitochondria: translation into the clinics. Biochim Biophys 
Acta 1792:1145–1158 pii]10.1016/j.bbadis.2009.01.006
 100. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next 
generation. Cell 144:646–674
 101. Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meet-
ing the metabolic requirements of cell proliferation. Annu Rev 
Cell Dev Biol 27:441–464
 102. Brand KA, Hermfisse U (1997) Aerobic glycolysis by prolifer-
ating cells: a protective strategy against reactive oxygen species. 
FASEB J 11:388–395
 103. Santamaria G, Martinez-Diez M, Fabregat I, Cuezva JM 
(2006) Efficient execution of cell death in non-glycolytic cells 
requires the generation of ROS controlled by the activity of 
mitochondrial H+-ATP synthase. Carcinogenesis 27:925–935. 
doi:10.1093/carcin/bgi315
 104. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, San-
tamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, 
Reed JC (2002) The bioenergetic signature of cancer: a marker 
of tumor progression. Cancer Res 62:6674–6681
 105. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso 
AM, Cejas P, Hardisson D, Fresno Vara JA, Belda-Iniesta C, 
Gonzalez-Baron M, Cuezva JM (2005) Breast carcinomas fulfill 
the Warburg hypothesis and provide metabolic markers of can-
cer prognosis. Carcinogenesis 26:2095–2104
 106. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, 
Berrendero JR, Pozo-Rodriguez F, Lopez-Encuentra A, Balles-
tin C, Cuezva JM (2007) Loss of the mitochondrial bioenergetic 
capacity underlies the glucose avidity of carcinomas. Cancer 
Res 67:9013–9017
 107. Wei S, Fukuhara H, Kawada C, Kurabayashi A, Furihata M, 
Ogura S, Inoue K, Shuin T (2015) silencing of ATPase inhibi-
tory factor 1 inhibits cell growth via cell cycle arrest in bladder 
cancer. Pathobiology 82:224–232. doi:10.1159/000439027
 108. Gao YX, Chen L, Hu XG, Wu HB, Cui YH, Zhang X, Wang Y, 
Liu XD, Bian XW (2016) ATPase inhibitory factor 1 expression 
is an independent prognostic factor in non-small cell lung can-
cer. Am J Cancer Res 6:1141–1148
 109. Zhang C, Min L, Liu J, Tian W, Han Y, Qu L, Shou C (2016) 
Integrated analysis identified an intestinal-like and a diffuse-
like gene sets that predict gastric cancer outcome. Tumour Biol. 
doi:10.1007/s13277-016-5454-7
 110. Kurbasic E, Sjostrom M, Krogh M, Folkesson E, Grabau 
D, Hansson K, Ryden L, Waldemarson S, James P, Nimeus 
E (2015) Changes in glycoprotein expression between pri-
mary breast tumour and synchronous lymph node metastases 
or asynchronous distant metastases. Clin Proteomics 12:13. 
doi:10.1186/s12014-015-9084-7
 111. Yin T, Lu L, Xiong Z, Wei S, Cui D (2015) ATPase inhibitory 
factor 1 is a prognostic marker and contributes to proliferation 
and invasion of human gastric cancer cells. Biomed Pharmaco-
ther 70:90–96. doi:10.1016/j.biopha.2014.12.036
 112. Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, Wang J, 
Lu Z, Song X, Pei T, Qin Y, Li Y, Xie C, Sun B, Shi H, Li S, 
Meng X, Yang G, Pan S, Zhu J, Qi S, Jiang H, Zhang Z, Liu L 
(2014) Reciprocal activation between ATPase inhibitory factor 
1 and NF-kappaB drives hepatocellular carcinoma angiogen-
esis and metastasis. Hepatology 60:1659–1673. doi:10.1002/
hep.27312
Regulation of the  H+-ATP synthase by IF1: a role in mitohormesis 
1 3
 113. Wu J, Shan Q, Li P, Wu Y, Xie J, Wang X (2015) ATPase 
inhibitory factor 1 is a potential prognostic marker for the 
migration and invasion of glioma. Oncol Lett 10:2075–2080. 
doi:10.3892/ol.2015.3548
 114. Mourier A, Ruzzenente B, Brandt T, Kuhlbrandt W, Larsson 
NG (2014) Loss of LRPPRC causes ATP synthase deficiency. 
Hum Mol Genet 23:2580–2592. doi:10.1093/hmg/ddt652
 115. Quiros PM, Langer T, Lopez-Otin C (2015) New roles for 
mitochondrial proteases in health, ageing and disease. Nat 
Rev Mol Cell Biol 16:345–359. doi:10.1038/nrm3984
 116. Shen L, Zhi L, Hu W, Wu MX (2009) IEX-1 targets mito-
chondrial F1Fo-ATPase inhibitor for degradation. Cell Death 
Differ 16:603–612
 117. Faccenda D, Tan CH, Seraphim A, Duchen MR, Campan-
ella M (2013) IF1 limits the apoptotic-signalling cascade 
by preventing mitochondrial remodelling. Cell Death Differ 
20:686–697. doi:10.1038/cdd.2012.163
 118. Jovaisaite V, Mouchiroud L, Auwerx J (2014) The mitochon-
drial unfolded protein response, a conserved stress response 
pathway with implications in health and disease. J Exp Biol 
217:137–143. doi:10.1242/jeb.090738
 119. Nargund AM, Pellegrino MW, Fiorese CJ, Baker BM, Haynes 
CM (2012) Mitochondrial import efficiency of ATFS-1 regu-
lates mitochondrial UPR activation. Science 337:587–590. 
doi:10.1126/science.1223560
 120. Benedetti C, Haynes CM, Yang Y, Harding HP, Ron D (2006) 
Ubiquitin-like protein 5 positively regulates chaperone gene 
expression in the mitochondrial unfolded protein response. 
Genetics 174:229–239. doi:10.1534/genetics.106.061580
 121. Haynes CM, Petrova K, Benedetti C, Yang Y, Ron D (2007) 
ClpP mediates activation of a mitochondrial unfolded protein 
response in C. elegans. Dev Cell 13:467–480. doi:10.1016/j.
devcel.2007.07.016
 122. Nargund AM, Fiorese CJ, Pellegrino MW, Deng P, Haynes 
CM (2015) Mitochondrial and nuclear accumulation of the 
transcription factor ATFS-1 promotes OXPHOS recovery 
during the UPR(mt). Mol Cell 58:123–133. doi:10.1016/j.
molcel.2015.02.008
 123. Zhao Q, Wang J, Levichkin IV, Stasinopoulos S, Ryan MT, 
Hoogenraad NJ (2002) A mitochondrial specific stress 
response in mammalian cells. EMBO J 21:4411–4419
 124. Aldridge JE, Horibe T, Hoogenraad NJ (2007) Discovery 
of genes activated by the mitochondrial unfolded protein 
response (mtUPR) and cognate promoter elements. PLoS One 
2:e874. doi:10.1371/journal.pone.0000874
 125. Dogan SA, Pujol C, Maiti P, Kukat A, Wang S, Hermans S, 
Senft K, Wibom R, Rugarli EI, Trifunovic A (2014) Tissue-
specific loss of DARS2 activates stress responses indepen-
dently of respiratory chain deficiency in the heart. Cell Metab 
19:458–469. doi:10.1016/j.cmet.2014.02.004
 126. Houtkooper RH, Mouchiroud L, Ryu D, Moullan N, Katsyuba 
E, Knott G, Williams RW, Auwerx J (2013) Mitonuclear pro-
tein imbalance as a conserved longevity mechanism. Nature 
497:451–457. doi:10.1038/nature12188
 127. Moullan N, Mouchiroud L, Wang X, Ryu D, Williams EG, 
Mottis A, Jovaisaite V, Frochaux MV, Quiros PM, Deplancke 
B, Houtkooper RH, Auwerx J (2015) Tetracyclines disturb 
mitochondrial function across eukaryotic models: a call 
for caution in biomedical research. Cell Rep. doi:10.1016/j.
celrep.2015.02.034
 128. Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, 
D’Amico D, Ropelle ER, Lutolf MP, Aebersold R, Schoon-
jans K, Menzies KJ, Auwerx J (2016) NAD+ repletion 
improves mitochondrial and stem cell function and enhances 
life span in mice. Science. doi:10.1126/science.aaf2693
 129. Shadel GS, Horvath TL (2015) Mitochondrial ROS signaling 
in organismal homeostasis. Cell 163:560–569. doi:10.1016/j.
cell.2015.10.001
 130. Nguyen T, Nioi P, Pickett CB (2009) The Nrf2-antioxidant 
response element signaling pathway and its activation by oxi-
dative stress. J Biol Chem 284:13291–13295. doi:10.1074/jbc.
R900010200
 131. Chae S, Ahn BY, Byun K, Cho YM, Yu MH, Lee B, Hwang D, 
Park KS (2013) A systems approach for decoding mitochondrial 
retrograde signaling pathways. Sci Signal 6:rs4. doi:10.1126/
scisignal.2003266
 132. Owusu-Ansah E, Song W, Perrimon N (2013) Muscle mito-
hormesis promotes longevity via systemic repression of insulin 
signaling. Cell 155:699–712. doi:10.1016/j.cell.2013.09.021
 133. Scialo F, Sriram A, Fernandez-Ayala D, Gubina N, Lohmus 
M, Nelson G, Logan A, Cooper HM, Navas P, Enriquez JA, 
Murphy MP, Sanz A (2016) Mitochondrial ROS produced via 
reverse electron transport extend animal lifespan. Cell Metab 
23:725–734. doi:10.1016/j.cmet.2016.03.009
 134. Dillin A, Hsu AL, Arantes-Oliveira N, Lehrer-Graiwer J, Hsin 
H, Fraser AG, Kamath RS, Ahringer J, Kenyon C (2002) Rates 
of behavior and aging specified by mitochondrial function 
during development. Science 298:2398–2401. doi:10.1126/
science.1077780
 135. Lee SJ, Hwang AB, Kenyon C (2010) Inhibition of respiration 
extends C. elegans life span via reactive oxygen species that 
increase HIF-1 activity. Curr Biol 20:2131–2136. doi:10.1016/j.
cub.2010.10.057
 136. Mookerjee SA, Divakaruni AS, Jastroch M, Brand MD (2010) 
Mitochondrial uncoupling and lifespan. Mech Ageing Dev 
131:463–472. doi:10.1016/j.mad.2010.03.010
 137. Brand MD (2000) Uncoupling to survive? The role of mito-
chondrial inefficiency in ageing. Exp Gerontol 35:811–820
 138. Harman D (1956) Aging: a theory based on free radical and 
radiation chemistry. J Gerontol 11:298–300
 139. Smith DL Jr, McClure JM, Matecic M, Smith JS (2007) Calorie 
restriction extends the chronological lifespan of Saccharomyces 
cerevisiae independently of the Sirtuins. Aging Cell 6:649–662. 
doi:10.1111/j.1474-9726.2007.00326.x
 140. Ocampo A, Liu J, Schroeder EA, Shadel GS, Barrientos A 
(2012) Mitochondrial respiratory thresholds regulate yeast 
chronological life span and its extension by caloric restriction. 
Cell Metab 16:55–67. doi:10.1016/j.cmet.2012.05.013
 141. Lin SJ, Kaeberlein M, Andalis AA, Sturtz LA, Defossez PA, 
Culotta VC, Fink GR, Guarente L (2002) Calorie restriction 
extends Saccharomyces cerevisiae lifespan by increasing respi-
ration. Nature 418:344–348. doi:10.1038/nature00829
 142. Schulz TJ, Zarse K, Voigt A, Urban N, Birringer M, Ristow 
M (2007) Glucose restriction extends Caenorhabditis elegans 
life span by inducing mitochondrial respiration and increas-
ing oxidative stress. Cell Metab 6:280–293. doi:10.1016/j.
cmet.2007.08.011
 143. Zid BM, Rogers AN, Katewa SD, Vargas MA, Kolipinski MC, 
Lu TA, Benzer S, Kapahi P (2009) 4E-BP extends lifespan upon 
dietary restriction by enhancing mitochondrial activity in Dros-
ophila. Cell 139:149–160. doi:10.1016/j.cell.2009.07.034
 144. Pan Y, Schroeder EA, Ocampo A, Barrientos A, Shadel GS 
(2011) Regulation of yeast chronological life span by TORC1 
via adaptive mitochondrial ROS signaling. Cell Metab 13:668–
678. doi:10.1016/j.cmet.2011.03.018
 145. Johnson SC, Rabinovitch PS, Kaeberlein M (2013) mTOR 
is a key modulator of ageing and age-related disease. Nature 
493:338–345. doi:10.1038/nature11861
 146. Katic M, Kennedy AR, Leykin I, Norris A, McGettrick 
A, Gesta S, Russell SJ, Bluher M, Maratos-Flier E, Kahn 
CR (2007) Mitochondrial gene expression and increased 
 P. B. Esparza-Moltó et al.
1 3
oxidative metabolism: role in increased lifespan of fat-spe-
cific insulin receptor knock-out mice. Aging Cell 6:827–839. 
doi:10.1111/j.1474-9726.2007.00346.x
 147. Dell’agnello C, Leo S, Agostino A, Szabadkai G, Tiveron C, 
Zulian A, Prelle A, Roubertoux P, Rizzuto R, Zeviani M (2007) 
Increased longevity and refractoriness to Ca(2+)-dependent 
neurodegeneration in Surf1 knockout mice. Hum Mol Genet 
16:431–444. doi:10.1093/hmg/ddl477
 148. Pulliam DA, Deepa SS, Liu Y, Hill S, Lin AL, Bhattacharya 
A, Shi Y, Sloane L, Viscomi C, Zeviani M, Van Remmen H 
(2014) Complex IV-deficient Surf1(-/-) mice initiate mitochon-
drial stress responses. Biochem J 462:359–371. doi:10.1042/
BJ20140291
 149. Mishur RJ, Khan M, Munkacsy E, Sharma L, Bokov A, Beam 
H, Radetskaya O, Borror M, Lane R, Bai Y, Rea SL (2016) 
Mitochondrial metabolites extend lifespan. Aging Cell 15:336–
348. doi:10.1111/acel.12439
 150. Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, 
Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell 
MA, Nathanson DA, Lai A, Faull KF, Jiang M, Clarke SG, 
Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung 
ME, Reue K, Huang J (2015) 2-Hydroxyglutarate Inhibits 
ATP Synthase and mTOR Signaling. Cell Metab 22:508–515. 
doi:10.1016/j.cmet.2015.06.009
 151. Hansen M, Hsu AL, Dillin A, Kenyon C (2005) New genes tied 
to endocrine, metabolic, and dietary regulation of lifespan from 
a Caenorhabditis elegans genomic RNAi screen. PLoS Genet 
1:119–128. doi:10.1371/journal.pgen.0010017
 152. Kim HJ, Morrow G, Westwood JT, Michaud S, Tanguay RM 
(2010) Gene expression profiling implicates OXPHOS com-
plexes in lifespan extension of flies over-expressing a small 
mitochondrial chaperone, Hsp22. Exp Gerontol 45:611–620. 
doi:10.1016/j.exger.2009.12.012
 153. Sun X, Wheeler CT, Yolitz J, Laslo M, Alberico T, Sun Y, Song 
Q, Zou S (2014) A mitochondrial ATP synthase subunit inter-
acts with TOR signaling to modulate protein homeostasis and 
lifespan in Drosophila. Cell Rep 8:1781–1792. doi:10.1016/j.
celrep.2014.08.022
 154. Lapuente-Brun E, Moreno-Loshuertos R, Acin-Perez R, 
Latorre-Pellicer A, Colas C, Balsa E, Perales-Clemente E, Qui-
ros PM, Calvo E, Rodriguez-Hernandez MA, Navas P, Cruz R, 
Carracedo A, Lopez-Otin C, Perez-Martos A, Fernandez-Silva 
P, Fernandez-Vizarra E, Enriquez JA (2013) Supercomplex 
assembly determines electron flux in the mitochondrial elec-
tron transport chain. Science 340:1567–1570. doi:10.1126/
science.1230381
